Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Active not recruiting 5Recruiting 4Completed 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Specimen Handling 116pembrolizumab 112Magnetic Resonance Spectroscopy 99Carboplatin 83Cyclophosphamide 70Biopsy 63Cisplatin 59Paclitaxel 56Bevacizumab 56Gemcitabine 48Nivolumab 45fludarabine 39Dexamethasone 37atezolizumab 36Rituximab 36Pemetrexed 36Fluorouracil 36Docetaxel 35Leucovorin 32Doxorubicin 31venetoclax 30Radiotherapy 30Oxaliplatin 29Capecitabine 29Temozolomide 27Prednisone 26Cetuximab 26130-nm albumin-bound paclitaxel 25Standard of Care 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Sirolimus × 30 days × Clear all
NCT07162038 2026-06-05

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
155 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT07581704 2026-06-04

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

University of Iowa

Phase 1 Recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT06528301 2026-05-28

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Umoja Biopharma

Phase 1 Recruiting
106 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡